Cargando…

Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma

Immunotherapy treatments, particularly immune checkpoint blockade, can result in benefits in clinical settings. But many pre-clinical and clinical studies have shown that resistance to anti-PD1 therapy frequently occurs, leading to tumor recurrence and treatment failure, including in patients with h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Xiangyi, Zheng, Zhiying, Song, Guoxin, Zhang, Zihao, Liu, Hanyuan, Kang, Junwei, Sun, Guoqiang, Sun, Guangshun, Huang, Tian, Li, Xiao, Rong, Dawei, Wang, Ke, Tang, Weiwei, Xia, Yongxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257027/ https://www.ncbi.nlm.nih.gov/pubmed/35812439 http://dx.doi.org/10.3389/fimmu.2022.876048

Ejemplares similares

Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing
por: Hao, Xiaopei, et al.
Publicado: (2022)

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
por: Rong, Dawei, et al.
Publicado: (2023)

Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy
por: Sun, Guangshun, et al.
Publicado: (2022)

Treatment of patients with cancer using PD-1/PD-L1 antibodies: Adverse effects and management strategies (Review)
por: Sun, Guangshun, et al.
Publicado: (2022)

Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies
por: Cao, Hengsong, et al.
Publicado: (2022)

Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway
por: Guangshun, Sun, et al.
Publicado: (2022)

Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma
por: Kang, Junwei, et al.
Publicado: (2022)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Li, Zhitao, et al.
Publicado: (2021)

CHSY1 promotes CD8(+) T cell exhaustion through activation of succinate metabolism pathway leading to colorectal cancer liver metastasis based on CRISPR/Cas9 screening
por: Sun, Guangshun, et al.
Publicado: (2023)

Prenatal mucopolysaccharidosis VII: A novel pathogenic variant identified in GUSB gene
por: Poyatos‐Andújar, Antonio Miguel, et al.
Publicado: (2020)

Mucopolysaccharidosis VII in a Cat Caused by 2 Adjacent Missense Mutations in the GUSB Gene
por: Wang, P., et al.
Publicado: (2015)

Non-progressive Nonimmune Hydrops Fetalis Caused by a Novel Mutation in GUSB Gene
por: MOSALLANEJAD, Asieh, et al.
Publicado: (2020)

Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma
por: Sun, Guoqiang, et al.
Publicado: (2022)

Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges
por: Hao, Xiaopei, et al.
Publicado: (2021)

Molecular characterization and exclusion of porcine GUSB as a candidate gene for congenital hernia inguinalis/scrotalis
por: Beck, Julia, et al.
Publicado: (2006)

Tegaserod Maleate Inhibits Breast Cancer Progression and Enhances the Sensitivity of Immunotherapy
por: Li, Xiao, et al.
Publicado: (2022)

A Novel GUSB Mutation in Brazilian Terriers with Severe Skeletal Abnormalities Defines the Disease as Mucopolysaccharidosis VII
por: Hytönen, Marjo K., et al.
Publicado: (2012)

Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma
por: Tang, Weiwei, et al.
Publicado: (2023)

CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ
por: Hao, Xiaopei, et al.
Publicado: (2022)

m6A modification of circHPS5 and hepatocellular carcinoma progression through HMGA2 expression
por: Rong, Dawei, et al.
Publicado: (2021)

Is the BCR-ABL/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib?
por: Bonecker, Simone, et al.
Publicado: (2015)

Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges
por: Sun, Guoqiang, et al.
Publicado: (2021)

MGP promotes CD8(+) T cell exhaustion by activating the NF-κB pathway leading to liver metastasis of colorectal cancer
por: Rong, Dawei, et al.
Publicado: (2022)

STK39 enhances the progression of Cholangiocarcinoma via PI3K/AKT pathway
por: Hao, Xiaopei, et al.
Publicado: (2021)

The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer
por: Zheng, Wubin, et al.
Publicado: (2022)

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
por: Lei, Chuqi, et al.
Publicado: (2023)

First Report of a Patient with MPS Type VII, Due to Novel Mutations in GUSB, Who Underwent Enzyme Replacement and Then Hematopoietic Stem Cell Transplantation
por: Dubot, Patricia, et al.
Publicado: (2019)

Single-cell RNA sequencing in cancer: Applications, advances, and emerging challenges
por: Sun, Guangshun, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Epigenetics: Roles and therapeutic implications of non-coding RNA modifications in human cancers
por: Rong, Dawei, et al.
Publicado: (2021)

WNT5a in Colorectal Cancer: Research Progress and Challenges
por: Sun, Guangshun, et al.
Publicado: (2021)

circCORO1C promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing the expression of PD‐L1 through NF‐κB pathway
por: Wu, Fan, et al.
Publicado: (2021)

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
por: Ju, Feng, et al.
Publicado: (2023)

Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I
por: Kong, Xiangyi, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism
por: Dong, Hao, et al.
Publicado: (2022)

Upregulation of ADAR Promotes Breast Cancer Progression and Serves as a Potential Therapeutic Target
por: Li, Xiao, et al.
Publicado: (2021)

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
por: Xia, Yongxiang, et al.
Publicado: (2022)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
por: Qi, Yihang, et al.
Publicado: (2021)

Emerging Mechanisms and Treatment Progress on Liver Metastasis of Colorectal Cancer
por: Zheng, Wubin, et al.
Publicado: (2021)

LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway
por: Ji, Jie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_anpm8i7c9uhh64au6ns50kd3dl